NanoGroup S.A. and Auxilius Pharma, a company specializing in the development of value-added medicines (value added medicines), have signed a letter of intent (LOI). The document formalizes the start of negotiations for the potential acquisition by NanoGroup S.A. of a stake in Auxilius Pharma.

The signed document paves the way for the start of negotiations, conducting a due diligence process and working out the terms of a potential transaction.

Auxilius Pharma is focused on drug development in the area of cardiology. The company’s mission is to improve patient outcomes by providing value-added drugs in convenient dosage forms that benefit patients, healthcare professionals and payers.

The company’s most advanced project, AUX-001, is in Phase 1b clinical trials. It is an improved formulation of the popular drug nicorandil, allowing once-daily dosing for patients with chronic stable angina.

The Companies will report on subsequent activities in accordance with applicable regulations.

*It should be emphasized that the letter of intent does not create a legally binding commitment to carry out the transaction.

About Auxilius Pharma – Auxilius Pharma is a privately held pharmaceutical company that launched in 2019. The company operates in the field of value-added medicines, innovating in areas of high unmet medical need – such as chronic stable angina – with the intention of positively impacting public health. Auxilius Pharma’s R&D strategy is based on patient needs for access to affordable therapies for the treatment of chronic diseases, both in the United States and in other key markets.